The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has appointed Ken Herrmann, MD, MBA, as the next Editor-in-Chief of The Journal of Nuclear Medicine (JNM). Herrmann will begin a five-year term on January 1, 2027, with a transition period starting July 1, 2026.
JNM ranks seventh among 212 journals in the medical imaging category, according to Clarivate’s Journal Citation Reports, and is recognized as a leading journal in nuclear medicine, molecular imaging, and theranostics. The publication serves as a global resource for research and clinical developments in the field.
Herrmann will succeed Johannes Czernin, MD, who served as Editor-in-Chief for 10 years. During that period, JNM experienced significant growth, with expanded global reach and strengthened scientific rigor across the medical imaging community.
Currently chair of nuclear medicine at the University of Duisburg-Essen in Germany, Herrmann brings more than two decades of international leadership in nuclear medicine and theranostics. His experience spans clinical practice, translational research, and strategic management across Europe, North America, and Asia. He previously practiced at Memorial Sloan Kettering Cancer Center in New York and at the University of California, Los Angeles.
Herrmann completed medical training in Germany, a nuclear medicine residency in Munich, and earned an MBA from the University of Zurich. He has authored more than 700 publications and has served as a long-time contributor and associate editor for JNM.
In outlining future priorities, Herrmann emphasized strengthening global engagement and ensuring that the journal reflects scientific excellence, diversity, and leadership across continents. A detailed announcement on editorial priorities will be released on July 1.
Click here to read the original press release.
